Market closed

Corcept Therapeutics/$CORT

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Corcept Therapeutics

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Ticker

$CORT
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
Menlo Park, United States

Employees

352
Website
www.corcept.com

CORT Metrics

BasicAdvanced
$5.3B
40.50
$1.26
0.46
-

$5.3B

0.46

$59.90

$20.84

782K

3.7

3.509

0.995

1.063

13.00%

25.77%

40.5

8.361

8.37

8.37

36.855

39.67%

57.97%

21.22%

14.94%

What the Analysts think about CORT

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Corcept Therapeutics stock.

CORT Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CORT Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

CORT News

AllArticlesVideos
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

Business Wire·2 weeks ago
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes

Business Wire·1 month ago
Corcept Therapeutics' ALS drug fails in mid-stage trial

Corcept Therapeutics' ALS drug fails in mid-stage trial

Reuters·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CORT

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Corcept Therapeutics stock?

Corcept Therapeutics (CORT) has a market cap of $5.3B as of January 15, 2025.

What is the P/E ratio for Corcept Therapeutics stock?

The price to earnings (P/E) ratio for Corcept Therapeutics (CORT) stock is 40.5 as of January 15, 2025.

Does Corcept Therapeutics stock pay dividends?

No, Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Corcept Therapeutics dividend payment date?

Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders.

What is the beta indicator for Corcept Therapeutics?

Corcept Therapeutics (CORT) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.